Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 2
2008 1
2009 2
2011 2
2012 1
2013 1
2014 1
2015 1
2016 1
2018 1
2019 1
2020 2
2021 3
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Di-μ(2)-chlorido-bis-[chlorido(η-hexa-methyl-benzene)ruthenium(II)].
González-Torres Y, Espinosa-Jalapa N, Hernández-Ortega S, Le Lagadec R, Morales-Morales D. González-Torres Y, et al. Among authors: le lagadec r. Acta Crystallogr Sect E Struct Rep Online. 2009 Oct 17;65(Pt 11):m1369. doi: 10.1107/S1600536809041154. Acta Crystallogr Sect E Struct Rep Online. 2009. PMID: 21578121 Free PMC article.
Di-μ(2)-bromido-bis-[bromido(η-1,2,4,5-tetra-methyl-benzene)ruthenium(II)].
Espinosa-Jalapa N, Hernández-Ortega S, Le Lagadec R, Morales-Morales D. Espinosa-Jalapa N, et al. Among authors: le lagadec r. Acta Crystallogr Sect E Struct Rep Online. 2009 Nov 28;65(Pt 12):m1684. doi: 10.1107/S1600536809049642. Acta Crystallogr Sect E Struct Rep Online. 2009. PMID: 21578690 Free PMC article.
The unfolded protein response-glutathione metabolism axis: A novel target of a cycloruthenated complexes bypassing tumor resistance mechanisms.
Riegel G, Orvain C, Recberlik S, Spaety ME, Poschet G, Venkatasamy A, Yamamoto M, Nomura S, Tsukamoto T, Masson M, Gross I, Le Lagadec R, Mellitzer G, Gaiddon C. Riegel G, et al. Among authors: le lagadec r. Cancer Lett. 2024 Mar 31;585:216671. doi: 10.1016/j.canlet.2024.216671. Epub 2024 Jan 28. Cancer Lett. 2024. PMID: 38290658 Free article.
A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53.
Vidimar V, Licona C, Cerón-Camacho R, Guerin E, Coliat P, Venkatasamy A, Ali M, Guenot D, Le Lagadec R, Jung AC, Freund JN, Pfeffer M, Mellitzer G, Sava G, Gaiddon C. Vidimar V, et al. Among authors: le lagadec r. Cancer Lett. 2019 Jan;440-441:145-155. doi: 10.1016/j.canlet.2018.09.029. Epub 2018 Oct 17. Cancer Lett. 2019. PMID: 30339780
23 results